Bristol Myers Squibb

Bristol Myers Squibb raised its 2026 sales outlook in July, while Novo Nordisk expects its sales to be flat at best this year, yet Bristol Myers Squibb trades at the lower earnings multiple.

Bristol Myers Squibb shares last traded at USD 62.86 on September 25, 2026. The company reported Phase 3 data for ZENBEXUS in relapsed or refractory multiple myeloma.

Bristol Myers Squibb stock opened at USD 61.75 and moved between USD 61.39 and USD 62.28 before reaching USD 61.93 at 12:34 p.m. ET. The stock was ahead of the SPY ETF by 0.24 percentage points.

Bristol-Myers Squibb (NYSE:BMY) has picked Onco360 to join the restricted specialty pharmacy network for ZENBEXUS (iberdomide). ZENBEXUS, a newly approved therapy for certain multiple myeloma patients, will be dispensed through a Risk Evaluation and Mitig

Both face patent cliffs and pay generous dividends, but only one of them can tell you where its next wave of growth is coming from.